22:30 , Mar 16, 2017 |  BC Innovations  |  Targets & Mechanisms

Bone appétit!

Last week’s Nature publication of a hormone secreted by bone that suppresses appetite and can curb weight gain not only adds to the emerging picture of bone as a player in the endocrine system but...
07:00 , Jul 9, 2012 |  BioCentury  |  Strategy

Belviq breaks through

Arena Pharmaceuticals Inc. and partner Eisai Pharmaceuticals Co. Ltd. will have a fine line to walk as they market Belviq lorcaserin for obesity. They want to improve patient compliance, which historically has not been good...
08:00 , Feb 7, 2011 |  BioCentury  |  Product Development

Obesity Reset

Even after FDA rejected the advice of its advisory committee and requested a cardiovascular outcomes trial of Orexigen Inc.'s Contrave bupropion/naltrexone to treat obesity, companies with earlier stage programs remain hopeful they will be able...
07:00 , Aug 12, 2010 |  BC Innovations  |  Targets & Mechanisms

The GPCR-cancer connection

Researchers from Roche's Genentech Inc.unit have identified a host of somatic mutations and gene copy number alterations across human cancers that represent potential targets for the disease.1 Nineteen of the 112 candidate cancer genes identified...
07:00 , May 21, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease ...
08:00 , Feb 23, 2009 |  BC Week In Review  |  Clinical News

Velneperit: Phase IIb data

Shionogi & Co. Ltd., Osaka, Japan   Product: Velneperit ( S-2367)   Business: Endocrine   Molecular target: Neuropeptide Y receptor Y5 (NPY5R)   Description: Oral neuropeptide Y (NPY) Y5 receptor antagonist   Indication: Treat obesity   Endpoint: Change...
08:00 , Feb 23, 2009 |  BC Week In Review  |  Clinical News

Velneperit: Phase IIb data

Top-line data from a double-blind, U.S. Phase IIb trial in 656 modified intent-to-treat (mITT) patients showed that once-daily 800 and 1,600 mg velneperit in combination with a reduced calorie diet met the primary endpoint of...
08:00 , Jan 29, 2009 |  BC Innovations  |  Cover Story

Wising up to NPYs

In the mid-1990s, neuropeptide Y was thought to be a promising obesity target based on its activity in the CNS as a potent feeding stimulator. However, the approach didn't succeed and only one company is...